Oseltamivir phosphate does not take the place of receiving a flu vaccination
MONDAY, Aug. 8, 2016 (HealthDay News) — The first generic version of the flu medication Tamiflu has been approved by the U.S. Food and Drug Administration.
Tamiflu (oseltamivir phosphate) is used to treat patients 2 weeks of age and older who have had flu symptoms for no more than 48 hours. It’s also used for the prevention of flu in patients 1 year of age and older. The FDA approved Tamiflu in 1999.
Oseltamivir phosphate does not take the place of seasonal flu vaccination, the FDA emphasized.
The agency also said oseltamivir phosphate does not treat or prevent illnesses caused by infections other than the flu virus, and does not prevent bacterial infections that may happen with the flu.
.jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
